51
|
Neiman V, Keizman D, Sarid D, Lee JL, Sella A, Gottfried M, Hammers H, Eisenberger M, Carducci M, Sinibaldi V, Rosenbaum E, Peer A, Neumann A, Mermershtain W, Rouvinov K, Berger R, Yildiz I. Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.58] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
52
|
Yildiz Y, Akyol M, Alacacioglu A, Kucukzeybek Y, Asık N, Taskaynatan H, Varol U, Yildiz I, Oflazoglu U, Salman T, Ozaltas S, Tarhan M. Sexual satisfaction, anxiety, depression and quality of life amoung Turkish gynecological cancer patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw374.38] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
53
|
Keizman D, Sarid D, Lee JL, Sella A, Gottfried M, Hammers H, Eisenberger MA, Carducci MA, Sinibaldi V, Neiman V, Rosenbaum E, Peer A, Neumann A, Mermershtain W, Rouvinov K, Berger R, Yildiz I. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib. Oncologist 2016; 21:1212-1217. [PMID: 27382030 DOI: 10.1634/theoncologist.2015-0428] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Accepted: 05/05/2016] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Sunitinib is a standard treatment for metastatic clear cell renal cell carcinoma (mccRCC). Data on its activity in the rare variant of metastatic chromophobe renal cell carcinoma (mchRCC), are limited. We aimed to analyze the activity of sunitinib in a relatively large and homogenous international cohort of mchRCC patients in terms of outcome and comparison with mccRCC. METHODS Records from mchRCC patients treated with first-line sunitinib in 10 centers across 4 countries were retrospectively reviewed. Univariate and multivariate analyses of association between clinicopathologic factors and outcome were performed. Subsequently, mchRCC patients were individually matched to mccRCC patients. We compared the clinical benefit rate, progression-free survival (PFS), and overall survival (OS) between the groups. RESULTS Between 2004 and 2014, 36 patients (median age, 64 years; 47% male) with mchRCC were treated with first-line sunitinib. Seventy-eight percent achieved a clinical benefit (partial response + stable disease). Median PFS and OS were 10 and 26 months, respectively. Factors associated with PFS were the Heng risk (hazard ratio [HR], 3.3; p = .03) and pretreatment neutrophil-to-lymphocyte ratio (NLR) >3 (HR, 0.63; p = .02). Factors associated with OS were the Heng risk (HR, 4.1; p = .04), liver metastases (HR, 3.8; p = .03), and pretreatment NLR <3 (HR, 0.55; p = .03). Treatment outcome was not significantly different between mchRCC patients and individually matched mccRCC patients. In mccRCC patients (p value versus mchRCC), 72% achieved a clinical benefit (p = .4) and median PFS and OS were 9 (p = .6) and 25 (p = .7) months, respectively. CONCLUSION In metastatic chromophobe renal cell carcinoma, sunitinib therapy may be associated with similar outcome and toxicities as in metastatic clear cell renal cell carcinoma. The Heng risk and pretreatment NLR may be associated with PFS and OS. IMPLICATIONS FOR PRACTICE Data on the activity of sunitinib in metastatic chromophobe renal cell carcinoma (mchRCC) are limited. This study analyzed the activity of sunitinib in a cohort of mchRCC patients. Of 36 patients with mchRCC who were treated with first-line sunitinib, 78% achieved a clinical benefit. Median PFS and OS were 10 and 26 months, respectively. Treatment outcome was not significantly different between mchRCC patients and individually matched metastatic clear cell RCC patients.
Collapse
Affiliation(s)
- Daniel Keizman
- Department of Oncology, Meir Medical Center, Kfar Saba, Israel Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - David Sarid
- Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
| | - Jae L Lee
- Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
| | - Avishay Sella
- Department of Oncology, Assaf Harofeh Medical Center, Zerifin, Israel
| | - Maya Gottfried
- Department of Oncology, Meir Medical Center, Kfar Saba, Israel Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Hans Hammers
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
| | - Mario A Eisenberger
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
| | - Michael A Carducci
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
| | - Victoria Sinibaldi
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
| | - Victoria Neiman
- Department of Oncology, Rabin Medical Center, Petah Tikva, Israel
| | - Eli Rosenbaum
- Department of Oncology, Rabin Medical Center, Petah Tikva, Israel
| | - Avivit Peer
- Department of Oncology, Rambam Medical Center, Haifa, Israel
| | - Avivit Neumann
- Department of Oncology, Rambam Medical Center, Haifa, Israel
| | | | - Keren Rouvinov
- Department of Oncology, Soroka Medical Center, Beersheba, Israel
| | - Raanan Berger
- Department of Oncology, Sheba Medical Center, Tel Hashomer, Israel
| | | |
Collapse
|
54
|
Kilic L, Yildiz I, Sen FK, Erdem MG, Serilmez M, Keskin S, Ciftci R, Karabulut S, Ordu C, Duranyildiz D, Tas F. D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients. Cancer Biomark 2016; 15:405-11. [PMID: 25792472 DOI: 10.3233/cbm-150477] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND The aim of this study is to evaluate the correlation of coagulation tests with various clinicopathological variables and tumor markers among colorectal cancer (CRC) patients. MATERIALS AND METHODS Ninety-four CRC patients were included for evaluation of clinicopathological factors, coagulation assays and tumor marker levels. RESULTS Metastatic disease was related with elevated INR (p= 0.03). Stage III patients had higher D-dimer values compared with stage II patients (p= 0.03). Correlation of tumor markers indicated a tendency towards elevated D-dimer levels for CEA values higher than median (p= 0.01). High CA 19-9 levels were also associated with higher INR (p= 0.007). Elderly age, distant metastasis, high CEA, CA-19-9 and LDH levels were associated with poorer overall-survival. CEA level was the only independent prognostic factor in multivariate analysis. CONCLUSIONS Coagulation assays can be utilized as predictors of disease extent in CRC. Elevated D-dimer and INR values may indicate higher disease stage. Correlation of D-dimer levels with CEA supports their value for assessing tumor burden.
Collapse
Affiliation(s)
- Leyla Kilic
- Medical Oncology Department, Firat University Hospital, Elazig, Turkey
| | - Ibrahim Yildiz
- Medical Oncology Department, Institute of Oncology, Istanbul University, Capa, Istanbul, Turkey
| | - Fatma Karagoz Sen
- Medical Oncology Department, Institute of Oncology, Istanbul University, Capa, Istanbul, Turkey
| | | | - Murat Serilmez
- Biochemistry Department, Institute of Oncology, Istanbul University, Capa, Istanbul, Turkey
| | - Serkan Keskin
- Medical Oncology Department, Institute of Oncology, Istanbul University, Capa, Istanbul, Turkey
| | - Rumeysa Ciftci
- Medical Oncology Department, Institute of Oncology, Istanbul University, Capa, Istanbul, Turkey
| | - Senem Karabulut
- Medical Oncology Department, Institute of Oncology, Istanbul University, Capa, Istanbul, Turkey
| | - Cetin Ordu
- Medical Oncology Department, Bedii Gorbon Oncology Center, Avrupa Florence Nightingale Hospital, Sisli, Istanbul, Turkey
| | - Derya Duranyildiz
- Biochemistry Department, Institute of Oncology, Istanbul University, Capa, Istanbul, Turkey
| | - Faruk Tas
- Medical Oncology Department, Institute of Oncology, Istanbul University, Capa, Istanbul, Turkey
| |
Collapse
|
55
|
Abstract
Hydrazone chemistry is widely utilized in biomedical field as a means of bioconjugation protocol, especially in drug delivery field due to pH labile nature of this linkage. In the light of kinetics studies, the generally accepted mechanism for the hydrolysis of hydrazones involves two main steps, namely, nucleophilic addition of water molecule to the hydrazone molecule to form carbinolamine intermediate and subsequent decomposition of this intermediate into the hydrazine and aldehyde/ketone moieties. Hydrolysis of hydrazones is catalyzed in the acidic environments and is thought to proceed through several proton transfer steps. To the best of our knowledge, in the literature no detailed theoretical study has been reported related to the mechanism of hydrolysis. In this study, we evaluated the proposed mechanism with DFT calculations with M06-2X functional at the 6-311+g(d,p) level including conductor-like polarizable continuum model solvation model. We also analyzed possible proton transfer pathways and assessed energetics of each step.
Collapse
Affiliation(s)
- Ibrahim Yildiz
- Applied Mathematics & Sciences, Khalifa University , PO Box 127788, Abu Dhabi, UAE
| |
Collapse
|
56
|
Kilic L, Ordu C, Yildiz I, Sen F, Keskin S, Ciftci R, Pilanci KN. Current adjuvant treatment modalities for gastric cancer: From history to the future. World J Gastrointest Oncol 2016; 8:439-449. [PMID: 27190583 PMCID: PMC4865711 DOI: 10.4251/wjgo.v8.i5.439] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2015] [Revised: 01/24/2016] [Accepted: 02/24/2016] [Indexed: 02/05/2023] Open
Abstract
The discrepancy between the surgical technique and the type of adjuvant chemotherapy used in clinical trials and patient outcomes in terms of overall survival rates has led to the generation of different adjuvant treatment protocols in distinct parts of the world. The adjuvant treatment recommendation is generally chemoradiotherapy in the United States, perioperative chemotherapy in the United Kingdom and parts of Europe, and chemotherapy in Asia. These options mainly rely on the United States Intergroup-0116, United Kingdom British Medical Research Council Adjuvant Gastric Infusional Chemotherapy, and the Asian Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer and Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer trials. However, the benefits were evident for only certain patients, which were not very homogeneous regarding the type of surgery, chemotherapy regimens, and stage of disease. Whether the dissimilarities in survival are attributable to surgical technique or intrinsic biological differences is a subject of debate. Regardless of the extent of surgery, multimodal therapy may offer modest survival advantage at least for diseases with lymph node involvement. Moreover, in the era of individualized treatment for most of the other cancer types, identification of special subgroups comprising those who will derive more or no benefit from adjuvant therapy merits further investigation. The aim of this review is to reveal the historical evolution and future reflections of adjuvant treatment modalities for resected gastric cancer patients.
Collapse
|
57
|
Yildiz I, Bayır H, Saglam I, Sereflican M, Bilgi M, Yurttas V, Demirhan A, Tekelioglu UY, Kocoglu H. The effect of desflurane on postoperative olfactory memory. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2016; 20:2163-2167. [PMID: 27249619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
OBJECTIVE In this study, we investigated the effects of desflurane 6%, on olfactory memory. PATIENTS AND METHODS This is a prospective clinical study performed with 40 patients aged 18-60 who had elective surgery and American Society of Anesthesiologists (ASA) physical status I-III. The Brief Smell Identification Test (BSIT) was used for evaluating patients' olfactory memories before and after the surgery. Patients received standard general anesthesia protocol and routine monitoring. For induction, 1.5 mg/kg of fentanyl, 2 mg/kg of propofol, and 0.5 mg/kg of rocuronium bromide were administered. Anesthesia was maintained with the inhalational of anesthetic desflurane (6%). The scores are recorded 30 minutes before the surgery and when the Aldrete Recovery Score reached 10 in the postoperative period. Preoperative and postoperative results were compared and p-values <0.05 were considered statistically significant. RESULTS The patients' mean age was 41.1±12.0. Preoperative total correct answer rate to odorous substances was 92.7%, and postoperative rate was 92.1%. Percentage of the odor substance identification by the patients revealed no statistically significant difference when pre and post-operative rates have been compared (p-value >0.05). CONCLUSIONS We have observed for the first time in the literature that general anesthesia using desflurane (6%) did not affect short-term olfactory memory. Further studies will be necessary to confirm our findings with larger sample size.
Collapse
Affiliation(s)
- I Yildiz
- Department of Anesthesiology and Reanimation, Abant Izzet Baysal University Medical Faculty, Bolu, Turkey.
| | | | | | | | | | | | | | | | | |
Collapse
|
58
|
Ciftci R, Tas F, Bilgin E, Keskin S, Yildiz I, Duranyildiz D, Saip P, Karanlik H, Vatansever S. Clinical significance of serum protease-activated receptor 1 (PAR1) level in patients with breast cancer. Journal of Oncological Science 2016. [DOI: 10.1016/j.jons.2016.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
59
|
Bayir H, Yildiz I, Erdem F, Tekelioglu UY, Ozyalvacli ME, Bilgi M, Kocoglu H. Effect of perioperative inadvertent hypothermia on the ECG parameters in patients undergoing transurethral resection. Eur Rev Med Pharmacol Sci 2016; 20:1445-1449. [PMID: 27160113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
OBJECTIVE Perioperative inadvertent hypothermia (PIH) (core body temperature to < 36 °C) is a common event during surgery. PIH may result from multiple factors. Elderly urology patients are at greater risk than other patients for hypothermia. PIH may cause adverse postoperative cardiac clinical manifestations. Our study aimed to determine the effects of postoperative alteration of core body temperature on the ECG parameters in patients undergoing transurethral resection. PATIENTS AND METHODS Fifty-nine patients, 40-83 years of age, who were scheduled for elective Transurethral Resection Prostate and/or Bladder (TUR-P and/or TUR-B) were enrolled in the study. Patients with operation times more than 30 minutes were included. Core temperatures were measured and standard 12-lead ECG readings were taken before surgery and immediately upon arrival in the postanesthesia care unit. RESULTS 59 patients were included this study. Prevalence of PIH (< 36ºC) was (57.6%). The postoperative temperature was found to be significantly lower than the preoperative of all patients (preop 36.46±0.39; postop 35.68±0.59, paired sample t-test, p<0.001). Also in all patients, postoperative QTc dispersions were found to be significantly longer than the preoperative QTc dispersions (preop 59.66±32.69; postop 74.57±37.47 ms, p<0.05). When we divided the patients; hypothermic and normothermic, postoperative QTc dispersions were significantly different between two groups (68.23±33.43 ms, and 83.20±41.50 ms; p=0.009). CONCLUSIONS The prevalence of inadvertent intraoperative hypothermia in patients undergoing transurethral resection is relatively high. QTc dispersion of mild hypothermic patients was significantly longer than normothermic patients'.
Collapse
Affiliation(s)
- H Bayir
- Department of Anesthesiology and Reanimation, Abant Izzet Baysal University, Faculty of Medicine, Bolu, Turkey.
| | | | | | | | | | | | | |
Collapse
|
60
|
Ozmen Yildiz P, Yildiz I, Ozmen C, Karabacak M, Doven O. Relation between coronary artery calcium score and serum tenascin-C level in patients without known coronary artery disease. Acta Cardiol 2016; 70:633-9. [PMID: 26717210 DOI: 10.2143/ac.70.6.3120174] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
OBJECTIVE Presence of coronary artery disease (CAD) also in subjects without traditional risk factors leads to a search for new risk factors. Tenascin-C (TNC), an extracellular matrix glycoprotein is normally found in very low concentrations in tissues and serum of adults, whereas its expression is enhanced in case of pathological conditions accompanied by inflammation. This study aimed to investigate the relation between coronary artery calcium score (CACS)and serum TNC level. METHODS Ninety patients (age range, 18-75 years) presenting with chest pain but without known CAD were divided according to their CACSs as control (CACS = 0, n = 30), low CACS (CACS between 0 and 400, n = 30), and high CACS (CACS ≥ 400, n = 30) groups. The patients were questioned about risk factors and underwent laboratory analyses for biochemical parameters including TNC. RESULTS The mean TNC level was significantly higher in the high CACS group as compared to both the low CACS group and the control group [4.7 (0.03-30.7), 28 (0.7-212) and 84 (2-456) ng/mL, respectively; P < 0.01]. A positive correlation was determined between serum TNC level and CACS (r = 0.641, P < 0.001). In the ROC curve analysis, when the cut-off value for TNC was accepted as 8.09 ng/mL, the sensitivity and specificity in detecting patients with CACS > 100 (moderate or significant calcification) were 72% and 82%, respectively. CONCLUSION A significant relationship was found between CACS and serum TNC level. Thus, measurement of TNC level can be used in determining elevated CACS and thereby the risk for CAD.
Collapse
|
61
|
Salman T, Bilici A, Arslan C, Varol U, Yildiz I, Akyol M, Yildiz Y, Kucukzeybek Y, Alacacioglu A, Yilmaz U. Thrombin activatable fibrinolysis inhibitor, tissue factor pathway inhibitor, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.4_suppl.615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
615 Background: Thromboembolism is common in cancer patients.Thrombin activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI) and prothrombin fragment 1+2 (F1+2) are newly identified molecules involved in coagulation and fibrinolysis. The aim of this study was to investigate the relationship between clinicopathologic characteristics and TAFI, TFPI and F1+2 levels in patients with advanced colorectal cancer. Methods: Eighty-two patients (32 metastatic, 50 locally advanced disease) diagnosed with colorectal cancer in the medical oncology clinic, without history of thromboembolism, had not undergone an intervention, and not on medication affecting coagulation were included in the study. Serum TAFI, TFPI, and prothrombin F1+2 levels were evaluated via enzyme-linked immunosorbent assay. Clinicopathologic characteristics of the patients were investigated retrospectively from the medical records of the patients. Results: The plasma TAFI, TFPI, and prothrombin F1+2 levels were high in 70, 71, and 96% of the patients, respectively. Prothrombin F1+2 levels were higher among patients with lower performance scores. TFPI levels were higher among patients with tumor grades of 2 and 3. TAFI levels were higher among rectal cancer cases. Conclusions: There is an association between tumor grade and coagulation cascade. The higher prothrombin F1+2 levels, an indicator of active coagulation cascade, among patients with low performance scores may indicate that the coagulation cascade of these patients is more active. Higher TAFI levels among rectal cancer patients may be related to the natural course of the disease
Collapse
Affiliation(s)
| | - Ahmet Bilici
- Department of Medical Oncology, Istanbul Medipol University, Istanbul, Turkey
| | - Cagatay Arslan
- Medical Oncology Department, Izmir University, Medicine Faculty Hospital, Izmir, Turkey
| | - Umut Varol
- Medical Oncology Department, Izmir Katip Celebi University, Medicine Faculty Hospital, Izmir, Turkey
| | - Ibrahim Yildiz
- Medical Oncology Department, Izmir Katip Celebi University, Medicine Faculty Hospital, Izmir, Turkey
| | - Murat Akyol
- Medical Oncology Department, Izmir Katip Celebi University, Medicine Faculty Hospital, Izmir, Turkey
| | - Yasar Yildiz
- Medical Oncology Department, Izmir Katip Celebi University, Medicine Faculty Hospital, Izmir, Turkey
| | - Yuksel Kucukzeybek
- Medical Oncology Department, Izmir Katip Celebi University, Medicine Faculty Hospital, Izmir, Turkey
| | - Ahmet Alacacioglu
- Medical Oncology Department, Izmir Katip Celebi University, Medicine Faculty Hospital, Izmir, Turkey
| | - Ugur Yilmaz
- Medical Oncology Department, Izmir University, Medicine Faculty Hospital, Izmir, Turkey
| |
Collapse
|
62
|
Salman T, Yildiz E, Yildiz I, Yavuzer D, Unlu M, Varol U, Akyol M, Yildiz Y, Bayoglu V, Kucukzeybek Y, Alacacioglu A. Evaluation of c-kit (CD 117) expression as a prognostic factor in testicular germ cell tumors: An Izmir Oncology Group (IZOG) study. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.2_suppl.476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
476 Background: Little progress has been made in the management of testicular germ cell tumors (TGCTs). c-kit (CD 117) is a good target for cancer treatment and possesses an impressive role in the current oncological practice. We aimed to evaluate c-kit expression in early stage TGCTs as a prognostic factor. Methods: Patients with TGCTs who were referred to the Medical Oncology Clinic were included in our study before starting chemotherapy. Immunohistochemistry was performed on formalin-fixed and paraffinembedded three-micrometer thick sections with CD 117 Rabbit Anti c-kit in vitro gene kit. Biochemically, we utilized AFP and β-HCG Immunlite 2000 device with solid phase chemiluminescent immunometric method, and LDH Roche models with the DP-standardized UV method. AFP 0-15 ng/ml, β-HCG < 0.1 mlu/ml and LDH 240-480 mg/dl were considered as normal values. Results: Sixty-five patients were included in our study. Forty-one (63%) patients had nonseminoma tumors (NSGCTs) and 24 (37%) had seminoma. Statistically significant c-kit expression was found in patients with seminoma (p<0.0001). There was no difference between negative or positive c-kit expression in terms of clinicopathological characteristics, including preoperative serum levels of AFP, β-HCG, LDH, lymph node involvement, distant metastasis, and IGCCCG risk classification. No correlation was found between these parameters and 5-year progression free survival (PFS) rate except for tumor stage, presence of lymph node metastasis and IGCCCG score (p=0.001, p=0.04, and p=0.0001, respectively). Five-year PFS rate of patients with positive CD 117 was 72.2% (95% CI, 54.6-89.8), and6.6% (95% CI, 31.2-82.1) for those without CD 117 expression involvement (p=0.12). Conclusions: So far, there has been no significant breakthrough in the treatment of cisplatinrefractory TGCTs in the era of targeted therapies. No prognostic importance of c-kit expression has been found in our study. However, we believe that c-kit expression, in numerical terms, can be considered as a good prognostic factor for patients with TGCTs. The fact that all seminoma cases displayed positive c-kit expression is what we think has driven this result.
Collapse
Affiliation(s)
- Tarik Salman
- Medical Oncology Department, Izmir Katip Celebi University, Izmir, Turkey
| | - Elif Yildiz
- Istanbul Umraniye Research and Training Hospital, Department of Internal Medicine, Istanbul, Turkey
| | - Ibrahim Yildiz
- Izmir Katip Celebi University Medical Oncology Dept., Izmir, Turkey
| | - Dilek Yavuzer
- Istanbul Kartal Research and Training Hospital, Department of Pathology, Istanbul, Turkey
| | - Mehtat Unlu
- Dokuz Eylul Univercity Medicine Faculty, Department of Pathology, Izmir, Turkey
| | - Umut Varol
- Izmir Katip Celebi University Medical Oncology Dept., Izmir, Turkey
| | - Murat Akyol
- Izmir Katip Celebi University Medical Oncology Dept., Izmir, Turkey
| | - Yasar Yildiz
- Izmir Katip Celebi University Medical Oncology Dept., Izmir, Turkey
| | - Vedat Bayoglu
- Izmir Katip Celebi University Medical Oncology Dept., Izmir, Turkey
| | | | | |
Collapse
|
63
|
Akyol M, Demir L, Alacacioglu A, Ellidokuz H, Kucukzeybek Y, Yildiz Y, Gumus Z, Bayoglu V, Yildiz I, Salman T, Varol U, Kucukzeybek B, Demir L, Dirican A, Sutcu R, Tarhan MO. The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study. Chemotherapy 2015; 61:57-64. [DOI: 10.1159/000440944] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2015] [Accepted: 09/07/2015] [Indexed: 11/19/2022]
Abstract
Background: A limited number of studies have been conducted on the effects of hormonal therapy with tamoxifen (TMX) or aromatase inhibitors (AIs) on plasma levels of leptin and adiponectin, as well as body composition in breast cancer (BC) patients. Therefore, we aimed to analyze the relationship between adipocytokines and body composition as well as the effects of TMX and AIs on plasma adiponectin, leptin, leptin/adiponectin ratio (LAR) and body composition. Methods: Patients were treated with either TMX or AI according to their menopausal status after adjuvant radiotherapy. Changes in body composition and serum leptin and adiponectin levels were evaluated. We recorded the type of hormonal therapy, BMI, waist/hip ratio (WHR), leptin and adiponectin levels at study entry, and after 6 and 12 months. Results: From baseline to the 6- and 12-month follow-ups, there were statistically significant increases in WHR (p = 0.003), fat mass (p = 0.041), and serum leptin (p < 0.001) and adiponectin levels (p < 0.001). The changes in body composition and serum leptin and adiponectin levels were similar in TMX and AI groups. A statistically significant decrease was found in total body water and LAR (p < 0.001). Although weight and body fat percentage increased, such increases were not statistically significant. A positive correlation was found between baseline BMI and serum leptin levels. This correlation was maintained at 6 and 12 months. The negative correlation found between serum adiponectin levels at baseline and baseline BMI did not last throughout the study. Conclusion: In this study, increased leptin and adiponectin levels and a decreased LAR were found in both AI and TMX groups. These changes might have occurred through both mechanisms of hormonal therapy and body composition changes. Therefore, AIs and TMX may exert their protective effects for BC patients by decreasing LAR rather than affecting leptin or adiponectin alone.
Collapse
|
64
|
Alacacioglu A, Ulger E, Varol U, Yildiz I, Salman T, Bayoglu V, Dirican A, Demir L, Akyol M, Yildiz Y, Kucukzeybek Y, Ataman G, Can H, Alacacioglu I, Tarhan MO. Depression, anxiety and sexual satisfaction in breast cancer patients and their partners-Izmir oncology group study. Asian Pac J Cancer Prev 2015; 15:10631-6. [PMID: 25605151 DOI: 10.7314/apjcp.2014.15.24.10631] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND We aimed to investigate anxiety, depression and sexual satisfaction levels and the effects of depression and anxiety upon the sexual satisfaction of Turkish breast cancer patients and their partners. MATERIALS AND METHODS Data were collected from one hundred breast cancer patients and their partners, using three forms: one covering information about socio-demographic characteristics of the patients, the Hospital Anxiety and Depression Scale (HADs) and the Golombok-Rust Inventory of Sexual Satisfaction (GRISS). RESULTS The frequencies, avoidance and touch subscores were statistically significantly high in the patients. Among those with high anxiety scores, the frequency, communication, satisfaction, touch, and anorgasmic subscale scores of GRISS were found to be significantly high. Among the partners whose anxiety scores were high, only the premature ejaculation subscale was statistically significant. It was determined that for partners with higher depression scores, the communication, satisfaction, avoidance, premature ejaculation and erectile dysfunction subscores of GRISS were statistically higher compared to partners with lower depression scores. CONCLUSIONS Patients' quality of life may be increased by taking precautions to reduce their and their partners' psychosocial and psychosexual concerns.
Collapse
Affiliation(s)
- Ahmet Alacacioglu
- Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey E-mail :
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
65
|
Akyol M, Demir L, Alacacioglu A, Ellidiokuz H, Kucukzeybekl Y, Yildiz Y, Bayoglu V, Yildiz I, Salman T, Varol U, Kucukzeybek B, Demir L, Dirican A, Sutcu R, Tarhan O. 1953 The effects of adjuvant endocrine treatment on the serum leptin, adiponectin and body composition in patients with breast cancer [Izmir Oncology Group(IZOG) Study]. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30901-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
66
|
Bayir H, Yildiz I. Postoperative atrial fibrillation and diastolic dysfunction; the contribution of autonomic nervous system function. Br J Anaesth 2015; 115:476-7. [PMID: 26269475 DOI: 10.1093/bja/aev278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
67
|
Bilgi M, Tekelioglu UY, Sit M, Demirhan A, Akkaya A, Yildiz I, Kocoglu H. Comparison of the effects of bispectral index-controlled use of remifentanil on propofol consumption and patient comfort in patients undergoing colonoscopy. Acta Gastroenterol Belg 2015; 78:314-318. [PMID: 26448413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
BACKGROUND AND STUDY AIMS In endoscopic procedures, propofol can be safely administered either alone or in conjunction with remifentanil. The aim of the study is to compare the effects of the administration of propofol alone and the administration of remifentanil in addition to propofol on patient and endoscopist satisfaction, preoperative hemodynamic response, and propofol consumption. MATERIALS AND METHODS A totally 60 patients were enrolled in the study. Propofol group (Group 1): A 0.4-mg/kg propofol bolus and 1 mg/kg/h maintenance infusion of propofol until a bispectral Index value of 70-75 was achieved. Propofol + remifentanil group (Group 2) received a 0.4 mg/kg propofol bolus dose and maintained with a 0.5 mg/kg/h infusion of propofol + 0.2 mcg/kg/min infusion of remifentanil. The infusion dose of remifentanil was maintained, and the propofol infusion dose was titrated until a BIS value of 70-75 was achieved. RESULTS In Group 1 (colonoscopic intervention 1 and 5 min) and Group 2 (colonoscopic intervention 10 min.), main blood pressure (MBP) value has a significant decrease. Hypotension occurred in 6 patients in group 1, while 12 patients in group 2. No significant difference was found between the Patient's endoscopist' satisfaction, MBP and heart rate. Propofol consumption was greater in group 1 than in group 2. When the Ramsay sedation levels of Group 1 and Group 2 were compared, a statistically significant difference was observed. CONCLUSIONS The addition of remifentanil to propofol may be an alternative to the use of alone propofol for sedation in colonoscopic interventions.
Collapse
|
68
|
Salman T, Yildiz E, Yildiz I, Yavuzer D, Unlu M, Varol U, Akyol M, Yildiz Y, Bayoglu V, Kucukzeybek Y, Alacacioglu A. Evaluation of c-kit (CD 117) expression as a prognostic factor in testicular germ cell tumors: an Izmir Oncology Group (IZOG) study. J BUON 2015; 20:1054-1060. [PMID: 26416056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
PURPOSE Despite the successful use of targeted and molecular therapies in other cancers, little progress has been made in the management of testicular germ cell tumors (TGCTs). c-kit (CD 117) is a good target for cancer treatment and possesses an impressive role in the current oncological practice. We aimed to evaluate c-kit expression in early stage TGCTs as a prognostic factor. METHODS Patients with TGCTs who were referred to the Medical Oncology Clinic and underwent curative surgical operation were included in our study before starting chemo- therapy. Immunohistochemistry was performed on formalin-fixed and paraffin-embedded three-micrometer thick sections with CD 117 Rabbit Anti c-kit in vitro gene kit. Biochemically, we utilized AFP and β-HCG Immunlite 2000 device with solid phase chemiluminescent immunometric method, and LDH Roche models with the DP-standardized UV method. AFP 0-15 ng/ml, β-HCG < 0.1 mlu/ml and LDH 240-480 mg/dl were considered as normal values. RESULTS Sixty-five patients were included in our study. Forty-one (63%) patients had non-seminoma tumors (NSGCTs) and 24 (37%) had seminoma. Statistically significant c-kit expression was found in patients with seminoma (p<0.0001). There was no difference between negative or positive c-kit expression in terms of clinicopathological characteristics, including preoperative serum levels of AFP, β-HCG, LDH, lymph node involvement, distant metastasis, and IGCCCG risk classification. No correlation was found between these parameters and 5-year progression free survival (PFS) rate except for tumor stage, presence of lymph node metastasis and IGCCCG score (p=0.001, p=0.04, and p=0.0001, respectively). Five-year PFS rate of patients with positive CD 117 was 72.2% (95% CI, 54.6-89.8), and 56.6% (95% CI, 31.2-82.1) for those without CD 117 expression involvement (p=0.12). CONCLUSION So far, there has been no significant breakthrough in the treatment of cisplatin-refractory TGCTs in the era of targeted therapies. No prognostic importance of c-kit expression has been found in our study. However, we believe that c-kit expression, in numerical terms, can be considered as a good prognostic factor for patients with TGCTs. The fact that all seminoma cases displayed positive c-kit expression is what we think has driven this result.
Collapse
Affiliation(s)
- Tarik Salman
- Izmir Katip Celebi University, Ataturk Research and Training Hospital, Department of Medical Oncology, Izmir, Turkey
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
69
|
Yildiz I, Bayir H. Effect of dexamethasone added to levobupivacaine used for TAP block. Hippokratia 2015; 19:285. [PMID: 27418798 PMCID: PMC4938486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Affiliation(s)
- I Yildiz
- Department of Anaesthesiology and Reanimation, Abant Izzet Baysal University, Faculty of Medicine, Bolu, Turkey
| | - H Bayir
- Department of Anaesthesiology and Reanimation, Abant Izzet Baysal University, Faculty of Medicine, Bolu, Turkey
| |
Collapse
|
70
|
Akyol M, Ulger E, Alacacioglu A, Kucukzeybek Y, Bayoglu V, Yildiz Y, Yildiz I, Salman T, Varol U, Demir L, Dirican A, Gumus Z, Oktay Tarhan M. Quality of life in colorectal cancer patients: an Izmir Oncology Group (IZOG) study. J BUON 2015; 20:1015-1022. [PMID: 26416050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
PURPOSE To investigate the variables of quality of life (QoL) among Turkish patients with colorectal cancer (CRC). METHODS In this prospective study we investigated the QoL of Turkish CRC patients. Two hundred and twenty two patients with CRC were included. The sociodemographic form and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) were used. RESULTS The study group consisted of 142 males (64%) and 80 females (36%). The mean patient age was 55.68±11.387 years. The majority of the patients (36.9%) had local disease while advanced-stage disease and locally advanced stage disease had 32.2% and 28.8% of the patients; respectively. The mean QoL score was moderate (62.81± 27.0). The most common complaints were fatigue, economic difficulties and constipation. Gender, education level and disease stage were associated with QoL. Physical, role and social functioning were more adversely affected in female patients. Compared to women, men had significantly more favorable global QoL (p=0.044). Some functional scales were worse in advanced disease compared to other stages.These outcomes were statistically significant in the functional scales of global health (p=0.007), physical (p=0.03), cognitive (p=0.01) and emotional function (p=0.007). Patients with advanced disease had worse outcomes in some symptoms (nausea, vomiting, dyspnea, loss of appetite and financial distress). CONCLUSIONS Female gender and advanced disease were strongly associated with poorer QoL among Turkish CRC patients.
Collapse
Affiliation(s)
- Murat Akyol
- Department of Medical Oncology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
71
|
Akyol M, Kucukzeybek Y, Varol U, Yildiz I, Cokmert S, Bayoglu I, Yildiz Y, Demir L, Can A, Dirican A, Alacacioglu A, Tarhan M. P-049 First-line cisplatin plus bolus 5- Fluorouracil combination in patients with locally advanced and metastatic esophageal cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
72
|
Bayoglu IV, Kurtel G, Alacacioglu A, Varim C, Yildiz I, Kucukzeybek Y, Dirican A, Demir L, Yildiz Y, Akyol M, Tarhan MO. Can basal neutrophil/ lymphocytes ratio predict clinical outcome of melanoma patients? J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e20108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Ibrahim Vedat Bayoglu
- Sakarya University, Sakarya Education and Research Hospital, Medical Oncology, Sakarya, Turkey
| | - Gozde Kurtel
- Katip Celebi University, Ataturk Education and Research Hospital, Medical Oncology, Izmir, Turkey
| | - Ahmet Alacacioglu
- Katip Celebi University, Ataturk Education and Research Hospital, Medical Oncology, Izmir, Turkey
| | - Ceyhun Varim
- Sakarya University, Sakarya Education and Research Hospital, Medical Oncology, Sakarya, Turkey
| | - Ibrahim Yildiz
- Katip Celebi University, Ataturk Education and Research Hospital, Medical Oncology, Izmir, Turkey
| | - Yuksel Kucukzeybek
- Katip Celebi University, Ataturk Education and Research Hospital, Medical Oncology, Izmir, Turkey
| | - Ahmet Dirican
- Katip Celebi University, Ataturk Education and Research Hospital, Medical Oncology, Izmir, Turkey
| | - Lutfiye Demir
- Katip Celebi University, Ataturk Education and Research Hospital, Medical Oncology, Izmir, Turkey
| | - Yasar Yildiz
- Katip Celebi University, Ataturk Education and Research Hospital, Medical Oncology, Izmir, Turkey
| | - Murat Akyol
- Katip Celebi University, Ataturk Education and Research Hospital, Medical Oncology, Izmir, Turkey
| | - Mustafa Oktay Tarhan
- Katip Celebi University, Ataturk Education and Research Hospital, Medical Oncology, Izmir, Turkey
| |
Collapse
|
73
|
Yildiz I, Sarid D, Lee JL, Chish A, Sella A, Gottfried M, Hammers HJ, Eisenberger MA, Carducci MA, Sinibaldi VJ, Neiman V, Rosenbaum E, Gez E, Peer A, Mermershtain W, Rouvinov K, Berger R, Keizman D. Patients (pts) with metastatic chromophobe renal cell carcinoma (mchRCC) treated with sunitinib (Su) therapy (tx): Analysis of an international database regarding outcome and comparison to clear cell histology (mccRCC). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e15619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Ibrahim Yildiz
- Istanbul University Institute of Oncology, Istanbul, Turkey
| | - David Sarid
- Division of Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel
| | - Jae-Lyun Lee
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - Adi Chish
- Genitourinary Oncology Service, Meir Medical Center, Kfar Saba, Israel
| | | | - Maya Gottfried
- Lung Cancer Unit, Meir Medical Center, Kfar Saba, Israel
| | - Hans J. Hammers
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | - Mario A. Eisenberger
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD
| | | | | | - Victoria Neiman
- Davidoff Cancer Center, Rabin Medical Center, Petach-Tikva, Israel
| | - Eli Rosenbaum
- Department of Oncology, Rabin Medical Center, Petah Tikva, Israel
| | - Eliahu Gez
- Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
| | | | | | | | | | - Daniel Keizman
- Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar-Saba, Israel
| |
Collapse
|
74
|
Akyol M, Ulger E, Alacacioglu A, Kucukzeybek Y, Yildiz Y, Bayoglu V, Gumus Z, Yildiz I, Salman T, Varol U, Ayakdas S, Tarhan MO. Sexual satisfaction, anxiety, depression and quality of life among Turkish colorectal cancer patients [Izmir Oncology Group (IZOG) study]. Jpn J Clin Oncol 2015; 45:657-64. [DOI: 10.1093/jjco/hyv051] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2015] [Accepted: 03/17/2015] [Indexed: 01/06/2023] Open
|
75
|
Kucukzeybek Y, Dirican A, Demir L, Yildirim S, Akyol M, Yildiz Y, Bayoglu IV, Alacacioglu A, Varol U, Salman T, Yildiz I, Can H, Tarhan MO. Adjuvant Chemotherapy and Prognostic Factors in Stage II Colon Cancer - Izmir Oncology Group Study. Asian Pac J Cancer Prev 2015; 16:2413-8. [DOI: 10.7314/apjcp.2015.16.6.2413] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
76
|
Vedat Bayoglu I, Yildiz I, Varol U, Cokmert S, Kucukzeybek Y, Alacacioglu A, Demir L, Dirican A, Akyol M, Yildiz Y, Oktay Tarhan M. Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer. J BUON 2015; 20:460-467. [PMID: 26011336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
PURPOSE Currently, there are several oxaliplatin combination regimens for first-line therapy of metastatic colorectal cancer (mCRC). In this study, we compared the survival outcomes of mCRC patients treated with bevacizumab in combination with either modified 5-FU/FA/oxaliplatin (mFOL- FOX6) or capecitabine/oxaliplatin (XELOX). METHODS We designed a two-arm retrospective study of mCRC patients with adenocarcinoma of the colon or rectum who were treated with bevacizumab and either mFOLFOX6 or XELOX and who had complete clinical and treatment data. We analysed their therapeutic responses, adverse events, progression-free survival (PFS), and overall survival (OS), and then determined whether there were any statistically significant differences. RESULTS A total of 131 patients (85 male; 65% and 46 female; 35%) were evaluated. Fifty-seven patients (43.5%) were treated with bevacizumab and mFOLFOX6 and 74 (56.5%) with bevacizumab and XELOX. The median PFS was 9.1 months (95% CI, 4.9-13.1) and 10 months (95% CI, 4.2-15.9) in the mFOLFOX6 and XELOX arms, respectively (p=0.610). The median OS was 29 months (95% CI, 21.6- 34.3) and 27.5 months (95% CI 20-38) in the mFOLFOX6 and XELOX arms (p=0.812), respectively. The most common reason for treatment withdrawal was disease progression (102 patients; 91%) and the most common grade 3-4 toxicity was neuropathy (≤14%). CONCLUSION Our results show that XELOX is a safe and effective alternative to mFOLFOX6 when combined with bevacizumab as first-line treatment for mCRC patients.
Collapse
Affiliation(s)
- Ibrahim Vedat Bayoglu
- Department of Medical Oncology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
77
|
Keizman D, Sarid D, Lee JL, Gottfried M, Maimon N, Hammers HJ, Eisenberger MA, Carducci MA, Sinibaldi VJ, Neiman V, Rosenbaum E, Gez E, Peer A, Mermershtain W, Rouvinov K, Berger R, Yildiz I. Patients with metastatic chromophobe renal cell carcinoma treated with sunitinib therapy: Analysis of an international database regarding outcome and comparison to clear cell histology (mccRCC). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.7_suppl.429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
429 Background: Sunitinib (Su) is a standard therapy (tx) for mccRCC. Data on its activity in the rare variant of metastatic chromophobe renal cell carcinoma (mchRCC) are limited by very small or heterogeneous (mixed histology with papillary type, or mixed targeted therapies) studies. We analyzed the activity of Su in a relatively large and homogenous international cohort of mchRCC pts, in terms of outcome and comparison to mccRCC. Methods: Records from mchRCC pts treated with first-line Su in 9 centers across 4 countries were retrospectively reviewed. Univariate and multivariate analyses of association between clinicopathologic factors and outcome were performed. Subsequently, mchRCC pts were individually matched to mccRCC pts. We compared the response rate (RR), progression free survival (PFS), and overall survival (OS) between the groups. Results: Between 2004-2014, 33 pts (median age 64, 45% male) with mchRCC were treated with Su as first-line tx. 76% had a prior nephrectomy. HENG risk was good 27%, intermediate 55%, and poor 18%. 33% were active smokers, and 30% users of angiotensin system inhibitors (ASIs). 55%, 27%, and 33% had lung, liver, and bone metastases, respectively. 48% had a pre-tx neutrophil to lymphocyte ratio (NLR) >3. 42% had dose reduction/tx interruption (DR/TI). Su-induced hypertension (HTN) occurred in 48%. 75% achieved a clinical benefit (partial response + stable disease), while 25% had disease progression within the first 3 months of tx. Median PFS and OS were 10 and 26 months, respectively. Factors associated with PFS were the HENG risk (HR 3.8, p=0.025) and pre-tx NLR >3 (HR 0.6, p=0.012). Factors associated with OS were the HENG risk (HR 4.27, p=0.027), liver metastases (HR 4.6, p=0.029), and pre-treatment NLR <3 (HR 0.5, p=0.04). Tx outcome was not significantly different between mchRCC pts and mccRCC pts, who were individually matched by HENG risk, nephrectomy/smoking status, pre-tx NLR, use of ASIs, DR/TI, and Su induced HTN. In mccRCC pts (p value versus mchRCC), 70% achieved a clinical benefit (p=0.58), and median PFS and OS were 9 (p=0.7) and 24 (p=0.6) months, respectively. Conclusions: In mchRCC pts, Su tx may have similar outcome to mccRCC pts.
Collapse
Affiliation(s)
- Daniel Keizman
- Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar-Saba, Israel
| | - David Sarid
- Division of Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel
| | - Jae-Lyun Lee
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - Maya Gottfried
- Lung Cancer Unit, Meir Medical Center, Kfar Saba, Israel
| | - Natalie Maimon
- Genitourinary Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar-Saba, Israel
| | - Hans J. Hammers
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
| | | | | | | | - Victoria Neiman
- Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel
| | - Eli Rosenbaum
- Department of Oncology, Rabin Medical Center, Petah Tikva, Israel
| | - Eli Gez
- Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
| | | | | | | | | | - Ibrahim Yildiz
- Istanbul University Institute of Oncology, Istanbul, Turkey
| |
Collapse
|
78
|
Bayir H, Yildiz I, Kocoglu E, Kurt A, Kocoglu H. Seroprevalence of hepatitis B, hepatitis C and HIV in ICU patients. Crit Care 2015. [PMCID: PMC4471206 DOI: 10.1186/cc14459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
79
|
Bayir H, Dagli R, Kaymaz H, Yildiz I, Kocoglu H. Troponin level as a predictor of prognosis in patients with acute ischemic stroke. Crit Care 2015. [PMCID: PMC4470650 DOI: 10.1186/cc14549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
80
|
Varol U, Yildiz I, Salman T, Karabulut B, Uslu R. Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer. Tumori 2014; 100:370-6. [PMID: 25296585 DOI: 10.1700/1636.17888] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The identification of clinical, biochemical and molecular markers to predict or monitor the efficacy of bevacizumab represents a major point in the treatment of patients with metastatic colorectal cancer. Studies and genetic analyses have been conducted to identify a predictive biomarker of bevacizumab efficacy. However, genes of the angiogenic pathway and angiogenic biomarkers vary substantially, thereby causing interindividual differences that complicate the identification of predictors for anti-vascular endothelial growth factor drugs like bevacizumab. So, the current challenge in bevacizumab treatment is to find predictive markers and implement them in clinical practice. In this review we have summarized the potential candidate biomarkers that may have a role in identifying patients who benefit most from bevacizumab treatment.
Collapse
|
81
|
Tas F, Karabulut S, Yildiz I, Duranyildiz D. Clinical significance of serum M30 and M65 levels in patients with breast cancer. Biomed Pharmacother 2014; 68:1135-40. [PMID: 25465151 DOI: 10.1016/j.biopha.2014.10.021] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2014] [Accepted: 10/18/2014] [Indexed: 12/24/2022] Open
Abstract
M30 and M65 are relatively new assays that detect different circulating forms of the epithelial cell structural protein cytokeratin18. The objective of this study was to determine the clinical significance of the serum levels of M30 and M65 in patients with breast cancer. A total of 80 patients with a pathologically confirmed diagnosis of breast cancer were enrolled into the study. Serum M30 and M65 concentrations were determined by the solid-phase sandwich ELISA method. Serum samples were obtained on first admission before any type of treatment. The median age at diagnosis was 52 years, range 30 to 81 years. The baseline serum M30 and M65 levels in patients with metastatic disease were significantly higher than those in the non-metastatic patients (P=0.017 and P=0.003, respectively). Moreover, serum M65 level was also elevated in patients with large tumor size (P=0.02). No correlation was found between these serum assay levels and response to chemotherapy (P>0.05). However, the significant relationship was found between the serum levels of M30 and M65 (rs=0.96, P<0.001). Neither serum M30 nor serum M65 had significantly effect on survival (P=0.50, and P=0.52, respectively). In conclusion, although both serum M30 and M65 levels are elevated in metastatic disease, no predictive and prognostic roles on survival were found in patients with breast cancer.
Collapse
Affiliation(s)
- Faruk Tas
- Institute of Oncology, University of Istanbul, Istanbul, Turkey.
| | - Senem Karabulut
- Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | - Ibrahim Yildiz
- Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | | |
Collapse
|
82
|
Sen F, Yildiz I, Odabas H, Tambas M, Kilic L, Karadeniz A, Altun M, Ekenel M, Serilmez M, Duranyildiz D, Bavbek S, Basaran M. Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma. Tumour Biol 2014; 36:1039-44. [PMID: 25326440 DOI: 10.1007/s13277-014-2708-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2014] [Accepted: 10/03/2014] [Indexed: 10/24/2022] Open
Abstract
M30 and M65 are circulating fragments of cytokeratin 18 released during apoptotic cell death and regarded as markers of cell death in patients with various tumor types. Our aim was to investigate the clinical and prognostic significance of the serum M30 and M65 concentrations in patients with advanced nasopharyngeal carcinoma. Thirty-two patients with nasopharyngeal cancer and 32 control subjects were investigated. Serum samples were obtained on first admission before any treatment was initiated. Serum M30 and M65 concentrations were measured by quantitative enzyme-linked immunosorbent assay. Median serum M30 (181.5 vs. 45.5 U/L, p < 0.001) and M65 (384.2 vs. 179.1 U/L, p < 0.001) concentrations were significantly higher in patients with advanced nasopharyngeal carcinomas than in controls. receiver operating characteristic (ROC) analysis showed that a cutoff for M30 of 225 U/L had a sensitivity of 62.5% and a specificity of 73.9% (area under the curve (AUC) = 0.592, 95% confidence interval (CI) 35.3-83.2, p = 0.44), while a cutoff for M65 of 423.4 U/L had a sensitivity of 75.1% and a specificity of 65.6% (AUC = 0.562, 95 % CI 36.0-76.5, p = 0.60). However, serum M30 and M65 were not important prognostic factors for progression-free survival. There were no statistically significant correlations between serum M30 and M65 concentrations and clinicodemographical variables. Serum M30 and M65 concentrations were found to have a diagnostic value in nasopharyngeal cancer. However, neither M30 nor M65 serum levels played a prognostic role in the outcome in nasopharyngeal cancer patients.
Collapse
Affiliation(s)
- Fatma Sen
- Department of Medical Oncology, Institute of Oncology, Istanbul University, Capa, 34390, Istanbul, Turkey
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
83
|
Varol U, Alacacioglu A, Yildiz I, Kucukzeybek Y, Uslu R. Gastric cancer with diffuse hepatic metastases and complete radiological response to triplet chemotherapy. J BUON 2014; 19:1128-1129. [PMID: 25536630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Affiliation(s)
- Umut Varol
- Medical Oncology Clinic, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
| | | | | | | | | |
Collapse
|
84
|
Bayoglu IV, Varol U, Yildiz I, Muslu U, Alacacioglu A, Kucukzeybek Y, Akyol M, Demir L, Dirican A, Cokmert S, Yildiz Y, Karabulut B, Uslu R, Tarhan MO. Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer. Asian Pac J Cancer Prev 2014; 15:7119-23. [DOI: 10.7314/apjcp.2014.15.17.7119] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
|
85
|
Bayoglu I, Kucukzeybek B, Küçükzeybek Y, Yildiz I, Akyol M, Varol U, Alacacioglu A, Demir L, Dirican A, Yildiz Y, Tarhan M. Expression and Prognostic Significance of Mesothelin in Her-2-Positive and Triple-Negative Breast Cancer Patients. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu359.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
86
|
Yildiz I, Ekenel M, Akman T, Kocar M, Uysal M, Kanitez M, Varol U, Bayoglu IV, Tural D, Kaplan MA, Avci N, Sürmeli Z, Dede İ, Ulaş A, Yazici O, Basaran M. Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial. Anticancer Res 2014; 34:4329-4334. [PMID: 25075067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM This study aimed to assess the clinical efficacy and toxicity of sunitinib, a targeted-agent, for non-clear cell renal cell carcinoma. PATIENTS AND METHODS Sixty-three patients with complete clinical data from 13 oncology Centers were retrospectively evaluated. Outcomes analyzed were objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and adverse events. RESULTS The median age of all patients, 38 men (60.3%) and 25 women (39.7%), was 63 years (range=25-82 years). Histological subtypes included 46 (88%) cases of papillary RCC, 10 of chromophobe, and 7 unclassified cases. Median treatment duration was seven months (range=2-86 months). At the time of this analysis, 52 patients had discontinued treatment, 33 of whom had died. Treatment discontinuation was due to disease progression in 43 patients, and toxicity in nine. Dose interruption was necessary in 22 (34.9%) patients, and dose reduction in 27 (42.9%). The objective response rate and disease control rate were 11.1% and 63.5%, respectively. The median PFS and OS were 7.6 months (95% confidence interval (CI)=5.5-9.7 months) and 22.0 months (95% CI=13.4-30.6 months), respectively, with 1-year rates of 64.7% and 33.7%, respectively. CONCLUSION Clinical outcome of the metastatic non-clear cell RCC patients with sunitinib treatment seemed to be worse than the historical data of clear cell RCC patients, in terms of PFS, OS and objective response. New and more effective targeted-therapies and better understanding of the underlying molecular processes are necessary to improve survival outcome for these patients.
Collapse
Affiliation(s)
- Ibrahim Yildiz
- Departments of Medical Oncology at: Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey
| | - Meltem Ekenel
- Departments of Medical Oncology at: Institute of Oncology, Istanbul University, Istanbul, Turkey
| | - Tulay Akman
- Departments of Medical Oncology at: Izmir Tepecik Training and Research Hospital, Izmir, Turkey
| | - Muharrem Kocar
- Departments of Medical Oncology at: Sanliurfa Education and Research Hospital, Sanliurfa, Turkey
| | - Mükremin Uysal
- Departments of Medical Oncology at: Afyon Kocatepe University, Afyonkarahisar, Turkey
| | - Metin Kanitez
- Departments of Medical Oncology at: Marmara University Hospital, Istanbul, Turkey
| | - Umut Varol
- Departments of Medical Oncology at: Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey
| | - Ibrahim Vedat Bayoglu
- Departments of Medical Oncology at: Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey
| | - Deniz Tural
- Departments of Medical Oncology at: Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Mehmet Ali Kaplan
- Departments of Medical Oncology at: Dicle University, Diyarbakir, Turkey
| | - Nilufer Avci
- Departments of Medical Oncology at: Balikesir State Hospital, Balikesir, Turkey
| | - Zeki Sürmeli
- Departments of Medical Oncology at: Ege University, Tulay Aktas Oncology Hospital, Izmir, Turkey
| | - İsa Dede
- Departments of Medical Oncology at: Ankara University Medical Faculty, Ankara, Turkey
| | - Arife Ulaş
- Departments of Medical Oncology at: Ali Osman Sonmez Oncology Training and Research Hospital, Bursa, Turkey
| | - Ozan Yazici
- Departments of Medical Oncology at: Ankara Numune Education and Research Hospital, Ankara, Turkey
| | - Mert Basaran
- Departments of Medical Oncology at: Institute of Oncology, Istanbul University, Istanbul, Turkey
| |
Collapse
|
87
|
Aki-Yalcin E, Ertan-Bolelli T, Taskin-Tok T, Ozturk O, Ataei S, Ozen C, Yildiz I, Yalcin I. Evaluation of inhibitory effects of benzothiazole and 3-amino-benzothiazolium derivatives on DNA topoisomerase II by molecular modeling studies. SAR QSAR Environ Res 2014; 25:637-649. [PMID: 25027467 DOI: 10.1080/1062936x.2014.923039] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
There has been considerable interest in DNA topoisomerases over the last decade, as they have been shown to be one of the major cellular targets in anticancer drug development. Previously we synthesized some benzothiazole derivatives and corresponding benzothiazolium forms, and tested their DNA inhibitory activity to develop novel antitumor agents. Among the 12 prepared compounds, compound BM3 (3-aminobenzothiazole-3-ium 4-methylbenzene sulfonate) exhibited extreme topoisomerase II inhibitory activity compared with the reference drug etoposide. We also tried to determine the DNA and enzyme binding abilities of BM3 and found that BM3 acted on topoisomerase II first at low doses, while it had also showed DNA minor groove binding properties at higher doses. In this study the interactions between DNA topoisomerase II and the compounds were examined in detail by molecular modelling studies such as molecular docking and pharmacophore analysis performed using Discovery Studio 3.5. As a result, it was found that benzothiazolium compounds exhibited a totally different mechanism than benzothiazoles by binding to the different amino acids at the active site of the protein molecule. 3-Aminobenzothiazoliums are worthy of carrying onto anticancer studies; BM3 especially would be a good anticancer candidate for preclinical studies.
Collapse
Affiliation(s)
- E Aki-Yalcin
- a Pharmaceutical Chemistry Department, Faculty of Pharmacy , Ankara University , Ankara , Turkey
| | | | | | | | | | | | | | | |
Collapse
|
88
|
Soydinc HE, Kan I, Dal T, Evsen MS, Sak ME, Ozler A, Turgut A, Yildiz I. Evaluation of the relationship between preeclampsia and seropositivity of infectious disease in maternal plasma. Clin Ter 2014; 164:e199-202. [PMID: 23868638 DOI: 10.7417/ct.2013.1568] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
PURPOSE The aim of the present study was to investigate the association between maternal infections and preeclampsia. MATERIALS AND METHODS Fifty-four pregnant women with preeclampsia (study group) and 54 healthy pregnant women (control group) were enrolled in this study. Chlamydia pneumoniae (CP), Mycoplasma hominis (MH), Helicobacter pylori (HP), Cytomegalovirus (CMV), Herpes simplex virus type 2 (HSV-2), and Toxoplasma gondii (TG) antibodies were analyzed in the maternal plasma of all of the participants. RESULTS There was no difference in the demographic data between groups. Maternal plasma seropositivity for CP IgM; MH IgA and IgG; HP IgM, IgA and IgG; TG, CMV and HSV-2 IgM and IgG were not significantly different between the preeclampsia and control groups. The seropositivity for CP IgG was significantly higher in women with preeclampsia versus the control women. CONCLUSIONS Our results suggested that preeclampsia is associated with CP IgG seropositivity.
Collapse
Affiliation(s)
- H E Soydinc
- Department of Gynecology and Obstetrics, Dicle University School of Medicine, Diyarbakir, Turkey.
| | | | | | | | | | | | | | | |
Collapse
|
89
|
Yilmaz S, Altinkanat-Gelmez G, Bolelli K, Guneser-Merdan D, Over-Hasdemir MU, Yildiz I, Aki-Yalcin E, Yalcin I. Pharmacophore generation of 2-substituted benzothiazoles as AdeABC efflux pump inhibitors in A. baumannii. SAR QSAR Environ Res 2014; 25:551-563. [PMID: 24905472 DOI: 10.1080/1062936x.2014.919357] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
RND family efflux pumps are important for multidrug resistance in Gram-negative bacteria. To date no efflux pump inhibitors for clinical use have been found, so developing the specific inhibitors of this pump system will be beneficial for the treatment of infections caused by these multidrug-resistant pathogens. A set of BSN-coded 2-substituted benzothiazoles were tested alone and in combination with ciprofloxacin (CIP) against the RND family efflux pump AdeABC overexpressor Acinetobacter baumannii SbMox-2 strain. The results indicated that the BSN compounds did not have antimicrobial activity when tested alone. However, if they were applied in combination with CIP, it was observed that the antibiotic had antimicrobial activity against the tested pathogen, possessing a minimum inhibitory concentration value that could be utilized in clinical treatment. A 3D-common features pharmacophore model was applied by using the HipHop method and the generated pharmacophore hypothesis revealed that the hydrogen bond acceptor property of nitrogen in the thiazole ring and the oxygen of the amide substituted at the second position of the benzothiazole ring system were significant for binding to the target protein. Moreover, three hydrophobic aromatic features were found to be essential for inhibitory activity.
Collapse
Affiliation(s)
- S Yilmaz
- a Pharmaceutical Chemistry Dept., Faculty of Pharmacy , Ankara University , Ankara , Turkey
| | | | | | | | | | | | | | | |
Collapse
|
90
|
Tas F, Karabulut S, Ciftci R, Yildiz I, Keskin S, Kilic L, Disci R. The behavior of Turkish cancer patients in fasting during the holy month of Ramadan. Jpn J Clin Oncol 2014; 44:705-10. [PMID: 24868079 DOI: 10.1093/jjco/hyu070] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVE Fasting during the holy month of Ramadan is one of the major obligations for all adult Muslims. We performed a survey of Turkish Muslim cancer patients to examine the extent of their fasting status and to compare various clinical characteristics of fasting and non-fasting cancer patients during the month of Ramadan. METHODS This study was conducted on 701 adult cancer patients who attended ambulatory patient care units answered the questionnaires. RESULTS The population comprised 445 women (63.5%), and the median age was 54 years. Before diagnosis of cancer, 93.1% of the patients used fast consists of completely (78.3%) and partial (14.8%). However, 15% of cases were fasting on the day of interview, either partially (7.4%) or completely (7.6%) with equal distributions. Patients who were females, those with good performance status, those without any comorbid disease, who had non-metastatic disease, those with history of surgery, those treated with radiotherapy and those being treated with oral chemotherapeutic agents were more likely to be fasting than others. The fasting ones had more prevalent among patients with lymphoma, urogenital cancer and breast cancer; conversely, the rate of fasting status among patients with lung and gastrointestinal cancer was quite low. Only 20.8% of all patients asked their physician whether it was alright for them to fast and physicians generally had a negative attitude towards fasting (83.2%). CONCLUSIONS Majority of cancer patients are not fasting during the month of Ramadan, and a small part of patients consult this situation to their physician.
Collapse
Affiliation(s)
- Faruk Tas
- Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | - Senem Karabulut
- Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | - Rumeysa Ciftci
- Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | - Ibrahim Yildiz
- Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | - Serkan Keskin
- Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | - Leyla Kilic
- Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | - Rian Disci
- Institute of Oncology, University of Istanbul, Istanbul, Turkey
| |
Collapse
|
91
|
Ciftci R, Tas F, Aksit E, Vatansever S, Karabulut S, Sen F, Yildiz I, Keskin S, Bozbey HU, Kilic L, Tilgen Yasasever C, Tastekin D. Clinical significance of serum macrophage migration inhibitory factor (MIF) level in breast cancer. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e11556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Rumeysa Ciftci
- Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey
| | - Faruk Tas
- Institute of Oncology, Istanbul University, Istanbul, Turkey
| | - Ece Aksit
- Istanbul University, Istanbul Medical Faculty, Institute of Oncology, Basic Oncology, Istanbul, Turkey
| | - Sezai Vatansever
- Department of Medical Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey
| | - Senem Karabulut
- Institute of Oncology, Istanbul University, Istanbul, Turkey
| | - Fatma Sen
- Hitit University, Corum Education and Research Hospital, Corum, Turkey
| | - Ibrahim Yildiz
- Istanbul University, Institute of Oncology, Istanbul, Turkey
| | - Serkan Keskin
- Okmeydani Training and Research hospital,department of medical oncology, Istanbul, Turkey
| | - Hamza Ugur Bozbey
- Istanbul University, Istanbul Medical Faculty, Institute of Oncology, Medical Oncology, Istanbul, Turkey
| | - Leyla Kilic
- Oncology of Institute, University of Istanbul, Istanbul, Turkey
| | - Ceren Tilgen Yasasever
- Istanbul University, Istanbul Medical Faculty, Institute of Oncology, Basic Oncology, Istanbul, Turkey
| | - Didem Tastekin
- Institute of Oncology, Istanbul University, Istanbul, Turkey
| |
Collapse
|
92
|
Sen F, Zobaci E, Erdemli HK, Kocabas R, Kilic L, Yildiz I. Serum inflammatory parameters as prognostic factors in patients with gastic cancer: Is serum albumin the best inflammotory biomarker predicting prognosis? J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e15002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Fatma Sen
- Hitit University, Corum Education and Research Hospital, Corum, Turkey
| | - Ethem Zobaci
- Hitit University, Corum Education and Research Hospital, Corum, Turkey
| | | | - Ramazan Kocabas
- Hitit University, Corum Education and Research Hospital, Corum, Turkey
| | - Leyla Kilic
- Oncology of Institute, University of Istanbul, Istanbul, Turkey
| | - Ibrahim Yildiz
- Istanbul University, Institute of Oncology, Istanbul, Turkey
| |
Collapse
|
93
|
Yildiz I, Ekenel M, Akman T, Kocar M, Uysal M, Kanitez M, Bayoglu V, Varol U, Tural D, Avci N, Kaplan MA, Surmeli Z, Dede I, Ulas A, Yazici O, Basaran M. Sunitinib in patients with metastatic non-clear renal cell carcinoma: A multicentric retpospective Turkish Oncology Group (TOG) trial. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e15602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Ibrahim Yildiz
- Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey
| | - Meltem Ekenel
- Oncology of Institute, University of Istanbul, Istanbul, Turkey
| | - Tulay Akman
- Dokuz Eylul University Medicine Faculty, Izmir, Turkey
| | - Muharrem Kocar
- Marmara University Hospital Medical Oncology Department, Istanbul, Turkey
| | - Mukremin Uysal
- Department of Medical Oncology, Afyon Kocatepe University, Afyonkarahisar, Turkey
| | - Metin Kanitez
- Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey
| | - Vedat Bayoglu
- Ataturk Education and Research Hospital Medical Oncology Department, Izmýr, Turkey
| | - Umut Varol
- Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey
| | - Deniz Tural
- Department of Medical Oncology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | | | | | - Zeki Surmeli
- Department of Medical Oncology, Ege University, Tulay Aktas Oncology Hospital, Izmir, Turkey
| | - Isa Dede
- Ankara University Medical Faculty Department of Medical Oncology, Ankara, Turkey
| | - Arife Ulas
- Ali Osman Sonmez Oncology Hospital, Department of Medical Oncology, Bursa, Turkey
| | - Ozan Yazici
- Ankara Numune Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Mert Basaran
- Institute of Oncology, Istanbul University, Istanbul, Turkey
| |
Collapse
|
94
|
Varol U, Dirican A, Yildiz I, Oktay E, Degirmenci M, Alacacioglu A, Barutca S, Karabulut B, Uslu R. First-line mono-chemotherapy in frail elderly patients with metastatic colorectal cancer. Asian Pac J Cancer Prev 2014; 15:3157-61. [PMID: 24815463 DOI: 10.7314/apjcp.2014.15.7.3157] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Unlike for fit elderly metastatic colorectal cancer (mCRC) patients, general approaches to initial treatment for the frail older mCRC patients are not clear. Our aim was to evaluate the efficiency and safety of first-line single-agent treatment in one such group. MATERIALS AND METHODS We retrospectively evaluated mCRC patients aged 70 or older with an Eastern Cooperative Oncology Group performance score of 2. They had no prior treatment and underwent first-line single-agent capecitabine or other monotherapies until disease progression or unacceptable toxicity. RESULTS Thirty-six patients were included. Most (n:28, 77.8%) were treated with capecitabine. One patient achieved a complete response and 5 patients had a partial response for an overall response rate of 16.6%. Twelve patients (33.3%) remained stable. Median progression free survival was 5 months (confidence interval (CI), %; 3.59-6.40) and median overall survival was 10 months (95 CI%; 8.1-11.8). Grade 3-4 toxicity was found in 6 patients (16.6%). Febrile neutropenia was not observed and there were no toxicity-associated deaths. CONCLUSIONS Capecitabine is a safe chemotherapeutic agent with moderate activity for first-line treatment of older metastatic colorectal cancer patients with limited performance status.
Collapse
Affiliation(s)
- Umut Varol
- Katip Celebi University Ataturk, Izmir, Turkey E-mail :
| | | | | | | | | | | | | | | | | |
Collapse
|
95
|
Lowrey J, Yildiz I. INVESTIGATION OF HETEROTROPHIC CULTIVATION POTENTIAL OF CHLORELLA VULGARIS AND TETRASELMIS CHUII IN CONTROLLED ENVIRONMENT WASTEWATER GROWTH MEDIA FROM DAIRY, POULTRY AND AQUACULTURE INDUSTRIES. ACTA ACUST UNITED AC 2014. [DOI: 10.17660/actahortic.2014.1037.147] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
96
|
Diaz-Tocados JM, Herencia C, Martinez-Moreno JM, Montes De Oca A, Rodriguez-Ortiz ME, Gundlach K, Buchel J, Steppan S, Passlick-Deetjen J, Rodriguez M, Almaden Y, Munoz-Castaneda JR, Nakano C, Hamano T, Fujii N, Matusi I, Mikami S, Tomida K, Mori D, Kusunoki Y, Shimomura A, Obi Y, Hayashi T, Rakugi H, Isaka Y, Tsubakihara Y, Jorgensen HS, Winther S, Hauge EM, Rejnmark L, Botker HE, Bottcher M, Svensson M, Ivarsen P, Sagliker Y, Demirhan O, Yildiz I, Paylar N, Inandiklioglu N, Akbal E, Tunc E, Tartaglione L, Rotondi S, Pasquali M, Muci ML, Mandanici G, Leonangeli C, Sotir N, Sales S, Mazzaferro S, Gigante M, Cafiero C, Brunetti G, Simone S, Grano M, Colucci S, Ranieri E, Pertosa G, Gesualdo L, Evenepoel P, Goffin E, Meijers B, Kanaan N, Bammens B, Coche E, Claes K, Jadoul M, Louvet L, Metzinger L, Buchel J, Steppan S, Massy ZA, Prasad B, St.Onge JR, Tentori F, Zepel L, Comment L, Akiba T, Bommer J, Fukagawa M, Goodkin DA, Jacobson SH, Robinson BM, Port FK, Evenepoel P, Viaene L, Poesen R, Bammens B, Meijers B, Naesens M, Sprangers B, Kuypers D, Claes K, Tominaga Y, Hiramitsu T, Yamamoto T, Tsujita M, Makowka A, G Yda M, Rutkowska-Majewska E, Nowicki MP, Takeshima A, Ogata H, Yamamoto M, Ito H, Kinugasa E, Kadokura Y, Dimkovic N, Dellanna F, Spasovski G, Wanner C, Locatelli F, Troib A, Assadi MH, Landau D, Rabkin R, Segev Y, Ciceri P, Elli F, Cappelletti L, Tosi D, Savi F, Bulfamante G, Cozzolino M, Barreto FC, De Oliveira RB, Benchitrit J, Louvet L, Rezg R, Poirot S, Jorgetti V, Drueke TB, Riser BL, Massy ZA, Pasquali M, Tartaglione L, Rotondi S, Muci ML, Mandanici G, Leonangeli C, Massimetti C, Utzeri G, Biondi B, Mazzaferro S, Verkaik M, Eringa EC, Musters RJ, Pulskens WP, Vervloet MG, Ter Wee PM, Schiller A, Onofriescu M, Apetrii M, Schiller O, Bob F, Timar R, Mihaescu A, Florea L, Mititiuc I, Veisa G, Covic A, Krause R, Kaase H, Stange R, Hopfenmuller W, Chen TC, Holick MF, Kawasaki T, Ando R, Maeda Y, Arai Y, Sato H, Iimori S, Okado T, Rai T, Uchida S, Sasaki S, An WS, Jeong E, Son SH, Kim SE, Son YK, Baxmann AC, Menon VB, Moreira SR, Medina-Pestana J, Carvalho AB, Heilberg IP, Bergman A, Qureshi AR, Haarhaus MH, Lindholm B, Barany P, Heimburger O, Stenvinkel P, Anderstam B, Wilson RJ, Copley JB, Keith MS, Preston P, Santos RSS, Moyses RMA, Silva BC, Jorgetti V, Coelho FMS, Elias RM, Wanderley RA, Ferreira LQO, Sena TCM, Valerio TR, Gueiros JEB, Gueiros APS, Awata R, Goto S, Nakai K, Fujii H, Nishi S, Sagliker Y, Dingil M, Paylar N, Kapur S, Kim B, Lee DY, Yang S, Kim HW, Moon KH, Palmer S, Teixeira-Pinto A, Saglimbene V, Macaskill P, Craig J, Strippoli G, Marks A, Nguyen H, Fluck N, Prescott G, Robertson L, Black C. CKD BONE DISEASE. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
97
|
Yildiz I, Sen F, Ekenel M, Darendeliler E, Bavbek S, Agaoglu F, Ozger H, Eralp L, Bilgic B, Basaran M. Survival and prognostic factors in adult patients with recurrent or refractory ewing sarcoma family tumours: a 13-years retrospective study in Turkey. In Vivo 2014; 28:403-409. [PMID: 24815845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM The aim of the present study was to evaluate the results of treatment and prognostic factors in adult patients with recurrent or refractory Ewing's sarcoma family tumors (ESFT). PATIENTS AND METHODS We retrospectively evaluated treatment outcomes of 54 consecutive patients with ESFT (aged 15 years or more) with complete medical records, who were treated with multimodal therapies after recurrence at the Istanbul University, Institute of Oncology. RESULTS The commonly used chemotherapy regimens at relapse were ifosfamide and etoposide (IE), ifosfamide and etoposide plus carboplatin (ICE), and oral etoposide. The median progression-free survival and overall survival for the entire group were 6.3 (95% confidence interval, 3.08-9.60) and 8.6 (95% confidence interval CI, 4.7-12.4) months, respectively. Multivariate analysis using a Cox proportional hazards model showed that non-IE/ICE chemotherapy regimens (p=0.003, hazard ratio=2.38) and the presence extrapulmonary metastases (p=0.045, hazard ratio=2.15) were associated with worse overall survival. CONCLUSION In primary refractory or relapsed ESFT, the presence of extrapulmonary metastases and treatment with salvage regimens other than ifosfamide and etoposide and/or carboplatin correlate with a poor prognosis.
Collapse
Affiliation(s)
- Ibrahim Yildiz
- Division of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
98
|
Ciftci R, Tas F, Yasasever CT, Aksit E, Karabulut S, Sen F, Keskin S, Kilic L, Yildiz I, Bozbey HU, Duranyildiz D, Vatansever S. High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer. Tumour Biol 2014; 35:6941-8. [PMID: 24740564 DOI: 10.1007/s13277-014-1932-y] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2014] [Accepted: 04/03/2014] [Indexed: 12/24/2022] Open
Abstract
The transforming growth factor beta 1 (TGFB1) is a regulatory cytokine with both tumor suppressor and tumor-promoting effects in breast cancer (BC) cell lines and tissue. Data about level of circulating TGFB1 and its prognostic significance in BC patients is conflicting. The objective of this study is to determine the clinical significance of the serum TGFB1 levels in BC patients. We enrolled 96 female patients with histopathologically diagnosed BC who did not receive chemotherapy (CT) or radiotherapy. Serum TGFB1 levels were measured by ELISA method and compared with 30 healthy controls. The mean serum TGFB1 level of BC patients was significantly higher than controls (0.08 vs. 0.04 ng/ml, p < 0.001). There was no significant difference according to known disease-related clinicopathological or laboratory parameters. Serum TGFB1 level had a significant impact on overall survival in both univariate (p = 0.01) and multivariate analysis (p = 0.013). Serum TGFB1 level is elevated in BC patients and has a favorable prognostic value. However, it has no predictive role on CT response.
Collapse
Affiliation(s)
- Rumeysa Ciftci
- Medical Oncology Department, Institute of Oncology, Istanbul University, Capa, Istanbul, Turkey,
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
99
|
Varol U, Yildiz I, Alacacioglu A, Uslu R. Anticancer therapy for breast cancer patients with skin metastases refractory to conventional treatments. Asian Pac J Cancer Prev 2014; 15:1885-7. [PMID: 24641425 DOI: 10.7314/apjcp.2014.15.4.1885] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Skin metastases of breast cancer are usually late events in the course of tumor progression and signify a poor prognosis. They may remain as a therapeutic challenge especially after failure of standard treatments. Topical interventions, together with or without radiotherapy, may only palliate the symptoms temporarily. However, there may be alternative treatment modalities for unresectable breast cancer skin metastases resistant to chemotherapy and radiotherapy. There are various genetic alterations in tumors and therapeutic potential of expression patterns for factors like epidermal growth factor receptor may have important clinical implications in case of disease refractory to the conventional treatments. Here, we clarified the therapeutic options and genetic alterations in skin metastatic breast cancer patients refractory to standard chemotherapeutics.
Collapse
Affiliation(s)
- Umut Varol
- Medical Oncology Clinic, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey E-mail :
| | | | | | | |
Collapse
|
100
|
Keskin S, Tas F, Karabulut S, Yildiz I, Kiliç L, Ciftci R, Vatansever S. The role of surgical methods in the treatment of anorectal malignant melanoma (AMM). Acta Chir Belg 2014. [PMID: 24494470 DOI: 10.1080/00015458.2013.11680958] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
PURPOSE Anorectal malignant melanoma (AMM) is a rare tumor with a poor prognosis. The aim of this study was to investigate the clinicopathological characteristics and treatment outcomes in patients with AMM. METHODS The study included 21 patients diagnosed with AMM between 2000 and 2010 that were evaluated with regard to age, sex, disease stage, treatment modality, and survival. Stage I, II, and III were defined as localized primary malignant melanoma, regional lymph node metastasis, and distant metastasis, respectively. RESULTS In all, 12 (57%) patients were female and 9 (43%) were male ; median age was 61 years (range : 30-84 years). Among the 21 patients, 7 (47%) underwent abdominoperineal resection and 8 (53%) were treated using wide local excision. Four (19%) patients were classified as stage I, 10 (48%) as stage II, and 7 (33%) patients as stage III. In total, 10 patients received adjuvant therapy. Median overall and progression-free survival was 12 and 9 months, respectively. The 1-year and 5-year overall survival estimates were 59% and 42%, and progression free survival were 49% and 7%, respectively. Patients aged > 60 years (P = 0.145), female patients (P = 0.076), patients with localized disease (P = 0.045), patients that underwent wide local excision (P = 0.619), and patients that received adjuvant therapy (P = 0.962) had longer survival. CONCLUSIONS The prognosis of AMM remains very poor and disease stage is the only predictor of survival. Abdominoperineal resection does not confer an advantage, in terms of survival, in patients with AMM.
Collapse
Affiliation(s)
- S. Keskin
- Department of Medical Oncology, Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | - F. Tas
- Department of Medical Oncology, Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | - S. Karabulut
- Department of Medical Oncology, Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | - I. Yildiz
- Department of Medical Oncology, Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | - L. Kiliç
- Department of Medical Oncology, Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | - R. Ciftci
- Department of Medical Oncology, Institute of Oncology, University of Istanbul, Istanbul, Turkey
| | - S. Vatansever
- Department of Medical Oncology, Institute of Oncology, University of Istanbul, Istanbul, Turkey
| |
Collapse
|